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Nuclear PI3K signaling in cell growth
and tumorigenesis
William J. Davis, Peter Z. Lehmann and Weimin Li *
College of Medical Sciences, Washington State University, Spokane, WA, USA
The PI3K/Akt signaling pathway is a major driving force in a variety of cellular functions.
Dysregulation of this pathway has been implicated in many human diseases including
cancer. While the activity of the cytoplasmic PI3K/Akt pathway has been extensively
studied, the functions of these molecules and their effector proteins within the nucleus
are poorly understood. Harboring key cellular processes such as DNA replication and
repair as well as nascent messenger RNA transcription, the nucleus provides a unique
compartmental environment for protein–protein and protein–DNA/RNA interactions
required for cell survival, growth, and proliferation. Here we summarize recent advances
made toward elucidating the nuclear PI3K/Akt signaling cascade and its key components
within the nucleus as they pertain to cell growth and tumorigenesis. This review covers
the spatial and temporal localization of the major nuclear kinases having PI3K activities
and the counteracting phosphatases as well as the role of nuclear PI3K/Akt signaling in
mRNA processing and exportation, DNA replication and repair, ribosome biogenesis, cell
survival, and tumorigenesis.
Keywords: nuclear signaling, PI3K/Akt/mTOR, cell growth, tumorigenesis, ribosome biogenesis, cell survival, DNA
damage, mRNA processing and export
Introduction
In the late 1970s and early 1980s, the existence of a nuclear phosphatidylinositol (PtdIns) cycle
was proposed (Manzoli et al., 1978, 1982). PtdIns consist of an inositol ring and two acyl chains.
The inositol ring moiety can be phosphorylated at different positions by PtdIns kinases to gen-
erate phosphoinositides (PIs), which can serve as primary or secondary signaling messengers.
Breakthroughs in the field were made when PtdIns 4-phosphate (PI4P), PtdIns 4,5-bisphosphate
[PI(4,5)P2], and the relevant kinases were identified within the nucleus and found to be regulated
independent of the cytosolic pools (Cocco et al., 1987; Divecha et al., 1991; Boronenkov et al.,
1998). Further work identified PI(3,4,5)P3, its kinases and phosphatases in the nucleus (Lind-
say et al., 2006; Song et al., 2012; Elong Edimo et al., 2013). Interestingly, the localization and
activities of these nuclear PIs and their kinases are not associated with any currently known mem-
branous structures, implying distinct nuclear functions separate from those in the cytoplasm.What
both the nuclear and the cytoplasmic compartments do have in common for the PtdIns 3-kinase
(PI3K)-mediated cascade is the kinase- and phosphatase-dependent and -independent regulation
of downstream biological effects.
The PI3K pathway mediates a wide range of cellular processes including cell survival, migra-
tion, division, differentiation, and proliferation. Mutations and dysregulation of key signal-relaying
enzymes in this pathway are frequently found in a variety of human pathological conditions
(Vanhaesebroeck et al., 2010). While this review focuses on the relationship of PI3K to cancer,
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the nuclear PI3K pathway is relevant in other human diseases
such as cardiovascular disorders. The nuclear localization and
translocation of specific PI3K and v-akt murine thymoma viral
oncogene homolog (Akt)/protein kinase B (PKB) isoforms under
different signaling events expand our current understanding of
the functions of these molecules (Figure 1). The combinational
insights provided by studies in both the cytosolic and nuclear
compartments will help construct a comprehensive picture of the
biological functions regulated by these enzymes.
Spatial and Temporal Positioning of
Nuclear PI3K Activity
PI(4,5)P2, the predominant precursor for PI(3,4,5)P3 generation,
was observed localizing to nuclear speckles (Boronenkov et al.,
1998). Disruption of the PI(4,5)P2 speckle pool, for example,
by depletion of the PDZ-domain-containing scaffolding protein
syntenin implicated in melanoma cell growth and differentia-
tion (Lin et al., 1998; Beekman and Coffer, 2008), impairs cell
survival and division in a signaling-dependent manner (Mortier
et al., 2005; Beekman and Coffer, 2008). In contrast to the local-
ization of PI(4,5)P2, PI(3,4,5)P3 was found in the nuclear matrix
around nuclear speckles (Lindsay et al., 2006). These studies sug-
gest that the two different nuclear phosphoinositide pools may
not overlap with each other. Perhaps the PI(3,4,5)P3 generated
from PI(4,5)P2 or other PI resources are targeted to the nuclear
matrix and other nuclear spots, such as the inner nuclear leaflet
FIGURE 1 | Nuclear distribution of the PI3K pathway. PI3K and many of
its associated kinases (orange), phosphatases (blue), and phosphoinositides
(yellow) reside natively in or translocate to the nucleus and nuclear
sub-compartments, adding complexity to the established functional
repertoire of the canonical PI3K pathway. The unique nuclear environment
gives rise to non-canonical functions and molecular interactions not present
in the cytoplasm. The uncertain role of nuclear PTEN in dephosphorylation of
nuclear PI(3,4,5)P3 is denoted by a dotted line.
and protein complexes, for protein docking or/and activation. It
is not clear whether this is a cell type-specific distribution or a
cell signaling, state-dependent change. It would be informative
to see the subnuclear localization of PI(4,5)P2, PI(3,4,5)P3, and
their kinases and phosphatases studied under the same signaling
conditions.
The nuclear production of PI(3,4,5)P3 reflects the activities of
various lipid kinases acting locally, and like PI(4,5)P2-binding
proteins (Lewis et al., 2011), factors bound to PI(3,4,5)P3 may
spatially and temporally alter the activities of the lipid kinases and
downstream signaling (Tanaka et al., 1999). Accumulating evi-
dence supports the notion that nuclear lipid kinases either exhibit
signal-dependent translocation from the cytoplasmic compart-
ment or are native to the nucleus, where their focal distribution
and activities are regulated by various signals (Neri et al., 1994;
Banfic et al., 2009; Kumar et al., 2011). So far, class I and II PI3Ks
and inositol polyphosphate multikinase (IPMK)/Ipk2 activities
have been observed within the nucleus.
Among the four class I PI3Ks (α, β, γ, and δ) that are impli-
cated in cancer (Fruman and Rommel, 2014), the p110β catalytic
isoform has been found in the nucleus (Kumar et al., 2011), where
it may regulate S-phase progression (Marqués et al., 2008), DNA
replication (Marqués et al., 2009), and DNA double strand break
(DSB) repair (Kumar et al., 2010). It was demonstrated that only
the nuclear and not the cytosolic pool of p110β was essential for
cell survival in mouse embryonic fibroblasts (MEFs), and that the
nuclear localization of p110β is mediated by the nuclear local-
ization signal (NLS)-containing C2 domain (Kumar et al., 2011).
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This is consistent with previous findings that mice deficient in
the p110β encoding gene PIK3CB are embryonic lethal before
E3 even at the blastocyst stage (Bi et al., 2002), days earlier than
deficiency of the gene encoding p110α (PIK3CA), which results
in embryonic lethality around E10 (Bi et al., 1999; Foukas et al.,
2006). The embryonic lethality of p110α and p110β deficiencies
indicates the importance of PI3K in cell growth and embry-
onic development, possibly through the generation of distinct
pools of PI(3,4,5)P3 required for the activation of downstream
signals necessary for cell survival. It was found that only dual
inhibition of p110α and p110β was sufficient to induce tumor
regression of BT474 and MCF7 xenografts and prevent partial
restoration of PI(3,4,5)P3 and phospho-Akt in HER2-amplified
cell lines (Costa et al., 2015; Schwartz et al., 2015). These find-
ings suggest that p110α and p110β have compensatory functions,
where inhibition of one isoform initiates a feedback mechanism
to activate the other. An earlier study indicated a similar com-
pensatory phenomenon where despite p110α and p110δ con-
tributing >90% of PI3K activity, only upon p110β inhibition was
there a decrease in proliferation in p110α- and p110δ-mutant
hematopoietic cells (Foukas et al., 2010). Furthermore, in MEFs,
which mainly express p110α and p110β, ablation of both iso-
forms was required to reduce proliferation as a small fraction
of total PI3K activity appeared sufficient to sustain cell viability
(Foukas et al., 2010). Further investigation into nuclear p110β
and its functions, apart from inducing Akt phosphorylation, may
provide valuable insight into therapeutics targeting the p110
isoforms.
Class II PI3K-C2α was observed at nuclear speckles, imply-
ing a role in mRNA transcriptional regulation (Didichenko and
Thelen, 2001). Indeed, speckle localization of PI3K-C2α corre-
lates well with splicing factors depending on the transcriptional
activities and signaling status of the cell (Didichenko and Thelen,
2001). It seems that the speckle-localized PI3K-C2α can be
phosphorylation-modified with no impact on its catalytic activity
during transcription inhibition, indicating non-canonical roles
of PI3K-C2α within the nucleus (Didichenko and Thelen, 2001).
PI3K-C2β was also found in the nuclear envelope, where tyro-
sine phosphorylation induced its lipid kinase activity for intranu-
clear PtdIns 3-phosphate (PI3P) generation (Visnjic et al., 2002),
as well as in the nuclear matrix, where it can be proteolytically
cleaved at the C2 domain for activation and local production of
PI3P and to a lesser extent PtdIns 3,4-bisphosphate [PI(3,4)P2]
(Sindic et al., 2006). Interestingly, the C2 domain of PI3K-C2β,
which contributes to phospholipid binding and negative regula-
tion of the catalytic activity, contains a nuclear localization motif
that is required for PI3K-C2β nuclear matrix translocation stim-
ulated by epidermal growth factor (EGF) (Arcaro et al., 1998;
Banfic et al., 2009). Nuclear PI3K-C2β has potential roles in G2/M
phase of cell cycle and growth regulation (Visnjic et al., 2003).
Similar to PI kinases which act on inositol rings bound to
acyl chains, inositol kinases, such as IPMK, phosphorylate inos-
itol rings without lipid tails to generate inositol 1,4,5,6/1,3,4,6-
tetrakisphosphate (IP4), inositol 1,3,4,5,6-pentakisphosphate
(IP5), and diphosphorylinositol tetrakisphosphate (PP-IP4) from
inositol 1,4,5-trisphosphate (IP3) (Odom et al., 2000; Shears,
2004). In addition to the role of IPMK as an inositol kinase,
IPMK exhibited wortmannin-insensitive and Akt signaling-
independent phosphoinositol 3-phosphate kinase activity within
the mammalian cell nucleus that out-performed nuclear PI3K for
PI(3,4,5)P3 production (Resnick et al., 2005). Moreover, recent
data suggest that IPMK enhances the transcriptional activity of
the nuclear receptor steroidogenic factor 1 (SF-1)/NR5A1 by
phosphorylating the solvent-exposed head group of its bound
ligand, PI(4,5)P2(Blind et al., 2012). Phosphorylation of SF-
1/PI(4,5)P2 generates SF-1/PI(3,4,5)P3 which induces formation
of a novel protein-lipid interface by stabilizing the region around
the ligand pocket (Blind et al., 2014). The protein-lipid inter-
face allows SF-1 to interact with PI-binding proteins such as
those containing PH-domains (Blind et al., 2014). It remains
unclear how PIs are loaded into SF-1. However, SF-1 can be
conjugated with SUMO-1 and thereby targeted to nuclear speck-
les (Chen et al., 2004). Sumoylation of SF-1, a plausible way of
sequestering SF-1 from its nuclear targets, is a potential mech-
anism by which SF-1 is localized and loaded with ligand via
direct uptake or by the action of phospholipid transport proteins
(PLTPs). Another point requiring clarification is how the inhibi-
tion of SF-1 by sumoylation and phosphatase and tensin homolog
(PTEN) dephosphorylation of SF-1-bound PI(3,4,5)P3 differ in
their downstream effects. Additionally, because class I and class
II PI3Ks and IPMK are all present within the nucleus, at nuclear
speckles, and control gene expression, further work is needed to
dissect the temporal, spatial, and functional assignments of these
kinases in the nucleus.
Consistent with nuclear PI3K activities, Akt, a canonical
downstream signaling effector of PI3K and an oncogene with
critical roles in cell growth, has also been found within the
nucleus. The nuclear presence of Akt can either be a result of
native localization or translocation from the cytoplasm. Many
targets of Akt can also be found within the nucleus such as the
nucleolar phosphoprotein nucleophosmin (NPM)/B23, which
dynamically shuttles between the nucleus and cytoplasm as well
as from the nucleolus to the nucleoplasm in S-phase of the cell
cycle (Borer et al., 1989; Itahana et al., 2003). Another Akt effector
is mammalian target of rapamycin complex 1 (mTORC1). Rap-
tor, a component of mTORC1, strongly associates with PtdIns
3,5-bisphosphate [PI(3,5)P2] and weakly with PI3P, presenting a
mechanism by which these 3-phosphorylated PIs might regulate
mTORC1 (Bridges et al., 2012). Interestingly, amino acid treat-
ment increased the cellular levels of PI3P and PI(3,5)P2, which in
turn induced localization of mTORC1 to late endosomes (Bridges
et al., 2012; Jin et al., 2014). The presence of PI(3,5)P2 in the
nucleus has not been documented. It is possible that PI(3,5)P2 has
a role in nuclear function and signaling but has thus far evaded
detection due to low abundance or requirements for specific
signaling conditions.
Three Akt isoforms encoded by different genes have been
identified in mammalian cells (Martelli et al., 2012). Akt1 and
Akt2 mainly localize at the plasma membrane and cytosol, and
may translocate to the nucleus after growth factor stimulation
(Andjelkovic et al., 1997; Meier et al., 1997). Akt3, however, is
predominantly localized within the nucleus and at the nuclear
envelope (Santi and Lee, 2010). Given the nuclear production of
PI(3,4)P2 and PI(3,4,5)P3 and their substrate binding capacities,
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the interaction of nuclear Akt(s) with these phospholipidmessen-
gers for activation in response to specific upstream signals must
be a dynamic and well-orchestrated process. Interestingly, the
3-phosphoinositide-dependent protein kinase 1 (PDK1), which
is known to phosphorylate and activate cytosolic Akt, is able
to shuttle into the nucleus in a PI3K signaling- and nuclear
PTEN-dependent manner, accumulating in the nucleus follow-
ing insulin stimulation (Lim et al., 2003). It is not clear whether
the nuclear localized PDK1 can activate Akt, and if the mecha-
nism of the activation is similar to that in the cytoplasm. Further
work to characterize the orchestration of cytosolic and nuclear
activation of Akt by PDK1 is needed to connect or differenti-
ate the two processes. Counteracting the nuclear localization of
Akt, treatment of cells with extracellular ATP or statins induced a
nuclear protein phosphatase- (PHLPP1/2, PP2A, and PTEN) and
p110β-dependent nuclear Akt depletion (Mistafa et al., 2010; Ye
et al., 2011). Balancing the kinase- and phosphatase-dependent
and independent functions of nuclear kinases and phosphatases
presents a significant challenge in the control of cell growth.
Nuclear PI(3,4,5)P3 Phosphatases
PI3K and Akt are kinases whose activities are antago-
nized by a variety of phosphatases. In addition to their
canonical roles, phosphatases often have phosphate removal-
independent functions. In the unique environment of the
nucleus, phosphatase-dependent and -independent functions are
essential for maintaining signaling equilibrium between activated
and inactivated states.
The lipid phosphatase and tumor suppressor PTEN is local-
ized to the cytosol as well as the nucleus (Chung and Eng, 2005;
Liu et al., 2005). It was reported that PTEN sumoylation at K254
is critical for its nuclear retention which, like its phosphatase
activity, is required for efficient genotoxic stress-induced DSB
repair (Bassi et al., 2013). It was also demonstrated that nuclear
localization without functional sumoylation of PTEN was not
sufficient to recruit the recombinase RAD51 to sites of DNA
damage to initiate DNA repair (Bassi et al., 2013). Addition-
ally, PTEN was found to translocate to the nucleus following
monoubiquitination (Trotman et al., 2007). These findings sug-
gest the importance of posttranslational modification of PTEN
for its nuclear functions. As described above, nuclear transloca-
tion of PTEN and other phosphatases was observed upon treat-
ment with statins and extracellular ATP in insulin-stimulated
A549 cells, where the phosphatases associated with phosphory-
lated Akt and facilitated nuclear Akt depletion (Mistafa et al.,
2010). Under these circumstances, activation of the phosphatases
coincided with a rapid nuclear translocation of proliferating
cell nuclear antigen (PCNA), association of PCNA and p21Cip1,
and cyclin D1 degradation (Mistafa et al., 2010). These changes
induce cell cycle arrest in response to an absence of nuclear Akt,
reiterating the importance of Akt localization within the nucleus.
Nuclear PTEN interacts with anaphase-promoting com-
plex/cyclosome (APC/C) and its substrate-specific activator,
CDH1, to promote APC-CDH1-mediated degradation of cyclin
B (Song et al., 2011). Importantly, it is nuclear localization
of PTEN and not its phosphatase activity that accounts for
regulation of the APC-CDH1 ubiquitination complex (Song
et al., 2011; Choi et al., 2014). On the other hand, APC and CDH1
facilitate removal of chromatin-bound PTEN, an important step
for mitotic exit (Choi et al., 2014). PTEN was shown to localize
to centromeres where it interacted with the DNA-binding cen-
tromeric protein CENP-C, a protein crucial for chromosome sta-
bility and integrity (Shen et al., 2007). The interaction of PTEN
with CENP-C is another phosphatase-independent function of
PTEN. Most, if not all, of the phosphatase activities of PTEN
have been assigned to counteracting accumulation of PI(3,4,5)P3
at the plasma membrane with no effect on nuclear PI(3,4,5)P3
despite the presence of PTEN in the nucleus (Lindsay et al.,
2006). This raises the possibility that PTEN phosphatase func-
tion requires conditions absent from the nucleus. The appar-
ent lack of PTEN phosphatase function and the presence of
the SH2 domain containing inositol 5-phosphatase 2 (SHIP2) in
the nucleus necessitates further investigation into the quenching
of nuclear PI3K activities and PI(3,4,5)P3 generation-triggered
downstream signaling.
SHIP2 was found to concentrate in the nucleus, at nuclear
speckles, and in the cytoplasm (Elong Edimo et al., 2011). Nuclear
SHIP2 interacts with the nuclear lamina proteins Lamin A/C
and the PP2A regulatory subunit PR130B (Elong Edimo et al.,
2011). Interestingly, the SHIP2-PR130B complex was shown to
translocate to the plasma membrane following EGF stimulation
(Zwaenepoel et al., 2010). Counter to the canonically antago-
nistic function of phosphatases to PI3K/Akt signaling, silenc-
ing SHIP2 was found to decrease activated nuclear Akt and
reduce cell adhesion and migration (Prasad, 2009). This impli-
cates SHIP2 as a tumor promoter, and indeed, SHIP2 was found
overexpressed in 44 percent of examined clinical breast cancer
specimens (Prasad et al., 2008). The oncogenic activity of SHIP2
may be attributable, in part, to the requirement of PI(3,4)P2 for
full Akt activation at the plasma membrane (Franke et al., 1997;
Scheid et al., 2002). Similarly, nuclear Aktmay rely on the nuclear
production of PI(3,4)P2 from PI(3,4,5)P3 by SHIP2 to maintain
or achieve full activation. It remains unclear how Akt activation
by PI(3,4)P2 and PI(3,4,5)P3 is balanced and how SHIP2 activity
is coordinated with the activity of other phosphatases.
Regulation of mRNA Processing and
Export by the Nuclear PI3K Pathway
Nuclear speckles are dynamic clusters of interchromatin gran-
ules enriched in mRNA processing factors (Spector and Lamond,
2011). Active transcripts were found around the periphery of
speckles throughout the nucleoplasm (Misteli and Spector, 1998).
The nuclear speckle localization of PI(4,5)P2, its kinases, and
PI3K isozymes suggest a role of the nuclear PI3K pathway in gene
transcription and mRNA processing.
PI(4,5)P2 is the predominant source for PI(3,4,5)P3 gen-
eration within cells. Considerable evidence supports that this
holds true for the nuclear compartment (Cocco et al., 1987;
Divecha et al., 1991; Boronenkov et al., 1998). Among the
PI(4,5)P2 generating enzymes, only phosphatidylinositol phos-
phate kinase (PIPK) type I alpha (PIPKIα), type I gamma isoform
4 (PIPKIγi4), type II alpha (PIPKIIα), and type II beta (PIPKIIβ)
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have been identified within the nucleus with PIPKIα localizing to
nuclear speckles, where it is involved in mRNA 3′-end process-
ing (Boronenkov et al., 1998; Ciruela et al., 2000; Mellman et al.,
2008; Schill and Anderson, 2009; Li et al., 2012).
Though PI(3,4,5)P3 has not been detected at nuclear speckles,
its phosphatase SHIP2 was identified at nuclear speckles dur-
ing mitosis when phosphorylated on S132 (Déléris et al., 2003;
Elong Edimo et al., 2011). Consistent with its phosphatase activ-
ity, down-regulation of SHIP2 induced PI(3,4,5)P3 accumula-
tion and Akt phosphorylation (Elong Edimo et al., 2011). These
results implicate the presence of PI3K activity at the active sites
of mRNA processing. This is supported by findings showing that
PI3K-C2α colocalizes with mRNA splicing factors at speckles
in a transcriptional activity-dependent manner (Didichenko and
Thelen, 2001) and that nuclear IPMK’s PI(3,4,5)P3-kinase activ-
ity is involved in transcriptional regulation (Odom et al., 2000;
Resnick et al., 2005). In addition to acting as a PI(3,4,5)P3 phos-
phatase, SHIP2 can interact with and dephosphorylate PI(4,5)P2
(Elong Edimo et al., 2011). This may potentially influence the
activities of the speckle PI(4,5)P2-regulated nuclear poly (A)
polymerase Star-PAP (Mellman et al., 2008) and PKCδ required
for Star-PAP control of DNA-damage response gene expression
(Li et al., 2012). The addition of a poly (A) tail to pre-mRNA by
poly (A) polymerases is important for stabilizing the transcript
and identifying it for nuclear exportation (Fuke andOhno, 2008).
Although absent from nuclear speckles, a nuclear PI(3,4,5)P3
pool was found within the nuclear matrix that may be involved
in the regulation of active transcription and mRNA process-
ing (Lindsay et al., 2006). This PI(3,4,5)P3 pool is insensitive
to nuclear PTEN expression (Lindsay et al., 2006). Although
PTEN has not been assigned to any particular nuclear structure,
a rapid perinuclear accumulation of PTEN has been observed
upon atorvastatin treatment (Mistafa et al., 2010). These studies
suggest the intriguing concept that different phosphotidylinos-
itol 3-phosphate kinase and phosphatase activities are required
for nuclear speckle- and nuclear matrix-targeted transcriptional
and post-transcriptional processes.
Post-transcriptional processing of mRNA is required for the
stability and export of the message for translation. It has been
shown that the PI3K/Akt pathway regulates mRNA export by
mediating the assembly of the transcription-export (TREX) com-
plex at the 5′-end of mRNA and the exon junction complex
(EJC) (Quaresma et al., 2013). As a key adaptor protein within
TREX, the mRNA export factor Aly was shown to be regulated
by nuclear PI3K activity through phosphorylation by nuclear
Akt and association with PI(4,5)P2 and PI(3,4,5)P3 (Okada
et al., 2008). Both phosphorylation by Akt and phosphoinosi-
tide association were required for Aly regulation of mRNA
export and cell proliferation (Okada et al., 2008). Remarkably,
it was demonstrated that selective export of gene transcripts,
including that of RAD51, are regulated by the pathway, sug-
gesting a signaling-guided mRNA export model (Okada et al.,
2008; Wickramasinghe et al., 2013). Supporting this concept,
the generation of PI(3,4,5)P3 by the PI3K-like activity of IPMK
appears to be required for the sequence-based selective export of
mRNAs encoding proteins involved in DNA repair by homolo-
gous recombination (HR) (Wickramasinghe et al., 2013). Nuclear
lipid kinase regulation of mRNA processing and export bridges
the outside-in and inside-out signaling mechanisms crucial for
adaptive protein synthesis and cell survival.
Ribosome Biogenesis
Ribosome biogenesis is the process by which cells synthe-
size and assemble components of the translational machinery
(Figure 2). The intimate connection between ribosome biogen-
esis and tumorigenesis is evident through the increased inci-
dence of cancer and risk of neoplasia when ribosome synthesis is
altered or upregulated (Loreni et al., 2014). With approximately
400 ribosomal DNA (rDNA) tandem repeats distributed across
five chromosomes in humans (Henderson et al., 1972; Birch and
Zomerdijk, 2008) and more than 60% of total cellular transcrip-
tion devoted to ribosome biosynthesis (Warner, 1999), it is not
surprising that this process is highly regulated and often dysfunc-
tional in cancer. The nucleus, specifically the nucleolus, lies at the
heart of the energetically demanding and complex synthesis of
ribosomes.
Ribosome biosynthesis is initiated in the nucleolus where ribo-
somal RNA (rRNA) is synthesized from rDNA, a process requir-
ing assembly of preinitiation complexes (PICs) for synthesis of
the primary 47S pre-rRNA transcript. The PIC is composed of
selectivity factor 1 (SL-1), upstream binding factor (UBF), the
RNA polymerase I (RNA pol I) transcription factor RRN3/TIF-
IA, RNA pol I and additional cofactors (Leary and Huang, 2001).
Though nucleolar localization of PI3K has not been defined, the
p110β and p85 subunits of PI3K were found to interact with
insulin receptor substrate-1 (IRS-1) and UBF within the nucleus
upon insulin-like growth factor-1 (IGF-1) stimulation, enhancing
rRNA synthesis (Drakas et al., 2004). This study supports another
observation that IGF-1- and nutrient-induced RNA pol I activa-
tion was completely dependent on PI3K activity and modulated
by mTOR (James and Zomerdijk, 2004). These findings provide
a mechanism by which nutrient status and growth factors reg-
ulate ribosome biogenesis through PI3K and MAPK signaling
acting on RNA Pol I, further establishing the roles of the PI3K
and MAPK pathways in cell growth and proliferation.
In addition to RNA pol I regulation of rRNA production,
ribosome biogenesis also involves RNA pol II and III for ribo-
somal protein-encoding pre-mRNA synthesis and 5S rRNA gen-
eration, respectively. As a cellular biosensor for energy, nutrient,
and growth status, mTOR has been implicated in multiple lev-
els of regulation of ribosome biogenesis including modulation
of the activities of RNA pol I, II, and III (Mayer and Grummt,
2006). Despite its central role in ribosome biogenesis, recent
studies in lymphoma and leukemic cells have shown that inhi-
bition of mTOR accounts for only part of the effect on rRNA
synthesis observed during Akt inhibition, suggesting that Akt-
mediated regulation of ribosome biogenesis occurs through
mTOR-dependent and -independent pathways (Chan et al., 2011;
Nguyen and Mitchell, 2013).
One of the roles of nuclear Akt in ribosome biogene-
sis involves regulation of rRNA synthesis. Akt stabilizes and,
through casein kinase 2α (CK2α), activates transcription initi-
ation factor-I (TIF-I), thus enhancing RNA pol I tethering to
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 April 2015 | Volume 3 | Article 24
Davis et al. Nuclear PI3K signaling
FIGURE 2 | Akt signaling in ribosome biogenesis. Ribosome biogenesis
occurs largely in the nucleolus. The pre-initiation complex is composed,
among other proteins, of RNA pol I, UBF, which binds the upstream control
element (UCE) and the core element (CE), and SL1, which binds the CE
(Knutson and Hahn, 2013). The products of RNA pol I and II and the
ribosomal proteins conjoin to form the early 90S pre-ribosome which is
processed to the pre-60S and pre-40S subunits (Grandi et al., 2002;
Tschochner and Hurt, 2003). Akt activates rDNA transcription by stabilizing
c-Myc, B23, and TIF-IA and through CK2 which also acts on TIF-IA. TIF-IA
interacts directly with SL1 and RNA pol I, enhancing rDNA transcription
(Miller et al., 2001). Through S6 kinase-1 (S6K-1), mTOR facilitates the
interaction between UBF and SL1 (Hannan et al., 2003). mTOR can bind 5S
rDNA promoters (Shor et al., 2010). The expression of rDNA transcribed by
RNA pol I, II, and III is enhanced by c-Myc (Eilers and Eisenman, 2008)
through direct rDNA binding and association with SL1, MAX (Amati et al.,
1993), and TFIIIB (Gomez-Roman et al., 2003). Processing of the pre-rRNA
transcripts involves Akt, c-Myc (Schlosser et al., 2003), mTORC1 (Iadevaia
et al., 2012), and B23 (Maden, 1990; Savkur and Olson, 1998).
rDNA promoters (Nguyen andMitchell, 2013). Akt also interacts
with nuclear PI(3,4,5)P3 and B23, interactions that likely involve
nuclear PI3K activities (Ahn et al., 2005; Lee et al., 2008; Kwon
et al., 2010). B23, protected from proteolytic cleavage by nuclear
Akt (Lee et al., 2008), is essential for the nucleolar localization and
regulation of rDNA transcription by c-Myc (Li and Hann, 2013),
a universal transcription factor and proto-oncoprotein (Dang,
2012; Nie et al., 2012).
The contribution of c-Myc to malignancy is well-established
and, in part, attributable to the promotion of ribosome biogen-
esis (Tansey, 2014). Among other roles, nuclear c-Myc controls
the transcription of UBF, directly binds rDNA in the nucle-
olus, mediates assembly of SL1 on rDNA promoters, facili-
tates UBF and TATA-binding protein (TBP) assembly into the
PIC, and increases histone acetylation and chromatin accessibil-
ity (Poortinga et al., 2004; Grandori et al., 2005). The interac-
tion of c-Myc with rDNA, found to occur at intergenic spacer
regions (IGSs), is important for epigenetically non-silenced
and promoter-hypomethylated rDNA attachment to the nuclear
matrix for transcriptional activation (Littlewood et al., 1995;
Shiue et al., 2014).Matrix attachment of rDNA occurs in response
to growth factor stimulation, a signal that may be relayed to
c-Myc through the PI3K pathway.
The purview and regulation of c-Myc are vast and fascinat-
ingly complex and are known to involve PI3K signaling through
Akt (Thomas and Tansey, 2011; Spender and Inman, 2014). In
the case of constitutive PI3K signaling, among other c-Myc acti-
vating events (Taub et al., 1982; Bahram et al., 2000; Yamamura
et al., 2012), c-Myc persists in the nucleus. Normally, c-Myc has a
short half-life of 15–20min due to rapid proteolytic degradation
initiated through phosphorylation of residue T58 by glycogen
synthase kinase-3 (GSK-3) (Gregory et al., 2003). The impor-
tance of c-Myc, and specifically T58, was shown in c-MycT58A
knock-in mice. c-MycT58A mice exhibited enhanced mammary
gland density, hyperplastic foci, cellular dysplasia, and mam-
mary carcinomas relative to wild-type mice, indicating increased
genomic instability and apoptotic suppression (Wang, 2011).
This is consistent with previous findings that inhibition of T58
phosphorylation enhances the transforming activity of c-Myc
by concomitantly decreasing c-Myc proteolysis and apoptotic
potential (Conzen et al., 2000). Akt increases the half-life of c-
Myc through GSK-3 by at least two means. First, Akt phos-
phorylates GSK-3, rendering it catalytically inactive and unable
to phosphorylate c-Myc on T58 (Wang et al., 1994). Second,
Akt facilitates nuclear export of GSK-3 by promoting its inter-
action with the chaperone protein Frat (Bechard et al., 2012).
Since GSK-3 lacks a nuclear export signal (NES), interaction
with Frat, which possesses a Crm1-dependent leucine-rich NES,
represents a mechanism by which GSK-3 is separated from
its nuclear targets and exported from the nucleus (Franca-Koh
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et al., 2002). Interestingly, Akt-independent regulation of GSK-
3 phosphorylation was identified in PI3Kγ knockout mice. The
kinase-independent activity of PI3Kγ inhibited the interaction
between the phosphatase PP2A and its methyltransferase, PPMT-
1, required for GSK-3 dephosphorylation and activation (Mohan
et al., 2013). To date, no definitive evidence has been presented
addressing a direct interaction between Akt and GSK-3 in the
nucleus. Acting independent of and with the transcription fac-
tor c-Myc, Akt directly and indirectly coordinates and promotes
various aspects of ribosome biogenesis.
It was known as early as the nineteenth century that cancer
cells have irregularly shaped and enlarged nucleoli (Giuseppe,
1896). We now know that these structural changes are associated
with cellular stress and often, disruptions in ribosome biogenesis.
Defects in nucleolar integrity result in release of ribosomal pro-
teins to the nucleoplasm, where ribosomal proteins like RPS14
can inactivate the E3-ubiquitin ligase activity of MDM2, stabiliz-
ing p53 and thereby inducing cell cycle arrest (Zhou et al., 2013).
RPS14 was also found to inhibit the transcriptional activity of
c-Myc by preventing recruitment of c-Myc and transformation-
transcription domain-associated protein (TRRAP) to c-Myc tar-
get gene promoters (Zhou et al., 2013). TRRAP is a PI3K-related
pseudokinase possessing a domain that is highly homologous to
the kinase domain of p110 subunits of PI3K but lacks the capacity
to phosphorylate substrates (McMahon et al., 1998). It is possi-
ble that TRRAP has a scaffolding role resembling that of PI3K,
and serves to stabilize protein complexes involved in ribosomal
biogenesis. Interestingly, TRRAP deletion significantly reduced
the expression of ribosomal proteins (Tapias et al., 2014). Addi-
tionally, two other ribosomal proteins, RPL5 and RPL11, were
found to cooperate in guiding the RNA-induced silencing com-
plex (RISC) to c-Myc mRNA while RPL11 also decreased his-
tone H4 acetylation at c-Myc target gene promoters, effectively
inhibiting c-Myc activity (Dai et al., 2007; Liao et al., 2014). It is
clear ribosomal proteins have crucial cellular functions as befits
their early emergence in evolution. The abundance and disper-
sal of ribosomal protein-coding genes throughout the genome
constitutes a unique sensor by which cells can detect genomic
aberrations (Kim et al., 2014). Genomic instability will often dis-
rupt the stoichiometric ratio of ribosomal proteins to rRNA or
cause the loss of nucleolar integrity, triggering p53-dependent
and -independent downstream effects (Alt et al., 2005). Can-
cerous cells, often exhibiting aneuploidy, must avoid triggering
these sensors. Exploitation of the activities of ribosomal pro-
teins for therapeutic intervention may someday prove a viable
method of cancer treatment. However, despite the role of ribo-
some biogenesis in satisfying the enhanced biosynthetic demand
of cancerous cells, the degree to which deregulation of ribo-
some biogenesis is causative of or auxiliary to tumorigenesis is
unclear.
DNA Replication and Damage Repair
Genomic integrity is under constant threat from both endoge-
nous and exogenous factors. Replication fidelity and repair of
damaged DNA ensures correct genetic information is carried
over during cell division and proliferation. These processes are
critical to genomic integrity and even slight deviations can result
in age-associated diseases and cancer (Hoeijmakers, 2001). The
PI3K signaling pathway has been implicated in many processes
of cell cycle regulation including DNA replication and damage
repair. Moreover, the various PI3K isoforms seem to be differ-
entially involved in cell cycle regulation. For instance, p110α is
activated at G1-phase entry and promotes PI(3,4,5)P3 and pro-
tein synthesis and gene expression whereas p110β activity peaks
in S-phase and regulates DNA synthesis and protein activities for
cytokinesis (Silio et al., 2012).
A central component of DNA replication and repair is PCNA,
a eukaryotic sliding clamp protein. Among its numerous func-
tions, PCNA triggers displacement of Polα/primase and acts as
a loading platform for the processive DNA polymerases (Maga
et al., 2000). PCNA requires the ATPase activity of the clamp
loader, replication factor C (RFC), to open and encircle double-
stranded DNA (Indiani and O’Donnell, 2006). Through a kinase-
independent function, p110β was found to interact with RFC1,
a subunit of the RFC complex, and thereby promote loading of
PCNA onto chromatin (Redondo-Muñoz et al., 2013). It is inter-
esting to note that p110β regulates PCNA loading through both
kinase-dependent and -independent activities as phosphoryla-
tion of the cell cycle inhibitor p21Cip1 on T145 releases PCNA
from its suppressive binding to p21Cip1 (Marqués et al., 2009).
Depletion of p110β with RNA interference (RNAi) increased the
expression levels of p21Cip1 and its association with PCNA, and
impaired PCNA-RFC association and loading onto chromatin
(Marqués et al., 2009; Redondo-Muñoz et al., 2013). The interac-
tion of PCNA and p21Cip1, occurring through the same domain
as the PCNA-DNA pol δ interaction, negatively regulates S-phase
progression (Cazzalini et al., 2003). The defects in S-phase pro-
gression induced by p110β knockdown can be recovered by
expression of a phosphomimetic p21Cip1 mutant (Marqués et al.,
2009), emphasizing the requirement for an active PI3K signaling
cascade in DNA replication.
Among DNA damage lesions, the most detrimental to
genomic integrity are DNA double-strand breaks (DSBs). Com-
mencement of DSB repair begins with establishment of large
protein complexes, referred to as foci, that contain DNA repair
proteins (Paull et al., 2000). Found at DNA damage foci,
p110β was required for the recruitment of Nijmegen breakage
syndrome-associated gene product, Nibrin/NBS1, and PCNA to
DSBs (Kumar et al., 2010). p110β-null MEFs exhibited spon-
taneous DSBs coincident with abnormal chromosome numbers
and chromosome breaks (Kumar et al., 2010). p110β RNAi in
NIH-3T3 cells and p110β deletion in MEFs rendered the cells
unable to activate the G2/M checkpoint (Kumar et al., 2010).
Consistent with a role in DNA replication, Akt has been impli-
cated in DNA damage repair. The finding that nuclear Akt
is phosphorylated at S473, normally targeted by mTORC2 (Li
et al., 2007), much earlier than cytoplasmic Akt after irradi-
ation in GM0719 cells (Boehme et al., 2008) indicates that
DNA damage induces rapid Akt activation in the nucleus. Like-
wise, irradiation-induced Akt nuclear translocation and accu-
mulation was observed, and Akt was found colocalized with
DSB marker γH2AX at DNA break sites (Liu et al., 2014).
These observations indicate the critical role of the nuclear
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p110β and Akt in the maintenance of genomic stability, the
disruption of which is a hallmark of cancer (Negrini et al.,
2010).
Nuclear PI3K regulation of the DNA damage response may
be mediated by factors such as the PI3K enhancer (PIKE) and
the proto-oncogene product c-Abl. The interaction of PIKE with
nuclear PI3K stimulates the lipid kinase activity of PI3K (Ye
et al., 2000) necessary to antagonize apoptosis (Ahn et al., 2004).
The non-receptor tyrosine kinase c-Abl directly binds and phos-
phorylates p85 in response to γ-irradiation, thereby inhibiting
PI3K activity (Yuan et al., 1997). Interestingly, this inhibitory
role of c-Abl on PI3K activity contrasts with the PI3K-activating
roles of the transforming Bcr-Abl and v-Abl variants, where an
N-terminal myristoylation of the Abl proteins was found to be
required to recruit PI3K to the plasma membrane for activation
and generation of PI(3,4,5)P3 (Varticovski et al., 1991). This PI3K
activation model more aptly applies to cytoplasmic membrane
structures as the Bcr-Abl fusion protein is found exclusively in
the cytoplasm and promotes apoptosis when entrapped in the
nucleus (Vigneri and Wang, 2001; Dixon et al., 2009). However,
since c-Abl is also present in the cell nucleus (Van Etten, 1999),
it is of interest to determine the degree to which it modulates
nuclear PI3K activity.
Cell Survival and Tumorigenesis
The early embryonic lethality of p110β-null mice indicates the
indispensability of p110β for cell survival, growth, and devel-
opment (Bi et al., 2002). Supporting this, NIH-3T3 cells lack-
ing p110β exhibited increased susceptibility to spontaneous and
γ-radiation-induced apoptosis (Kumar et al., 2011). Introduc-
ing wild-type p110β but not a C2-NLS p110β mutant (targeting
p110β to the cytoplasm) restored cell survival, reiterating the
critical role of nuclear p110β in cell viability (Kumar et al.,
2011). Interestingly, mice deficient in the catalytic activity of
p110β (K805R), other than incomplete penetrance of embry-
onic lethality, survived normally, but were born smaller than
wild-type controls and showed growth retardation (Ciraolo
et al., 2008). Despite the lack of recurrent mutations within the
p110β-encoding gene PIK3CB (Vanhaesebroeck et al., 2010), the
catalytic activity of p110β, but not that of p110α, is respon-
sible for active human epidermal growth factor receptor 2
(HER2)-induced mammary tumor cell growth and carcinogen-
esis (Ciraolo et al., 2008). Similarly, expression of constitutively
active p110β in the prostate of mice induced intraepithelial neo-
plasia (Lee et al., 2010). In addition, p110β, but not p110α, seems
to be responsible for prostate cancer development in the absence
of PTEN (Jia et al., 2008). Furthermore, overexpression of p110β
induced cell transformation in a MAPK/Erk- and Akt/mTOR-
dependent manner (Denley et al., 2008), indicating cross talk
between the two growth-regulating pathways during oncogenic
transformation. The capacity of PI3K for kinase-dependent
and -independent functions is not limited to p110β. The kinase
activity of p110γ was found to regulate Akt andMAPK phospho-
rylation while its kinase-independent function controls cAMP
and cGMP levels (Patrucco et al., 2004). These observations in
mice and cancer cells suggest that both the kinase-dependent
and -independent functions of p110β are required for cell growth
and proliferation.
Nuclear PI3K and its upstream regulator PIKE were found to
be necessary and sufficient to mediate the anti-apoptotic effect in
growth factor-stimulated PC12, HEK-293, and HeLa cells by pre-
venting DNA fragmentation initiated by a cell-free apoptosome
(Ahn et al., 2004). In this study, addition of PI(3,4,5)P3 to cell
nuclei mimicked the anti-apoptotic effect but required nuclear
Akt (Ahn et al., 2004). The effect of PI(3,4,5)P3 on apoptotic pre-
vention may be due to its control over the interaction between
Akt and the nuclear PI(3,4,5)P3 receptor, B23 (Kwon et al., 2010).
The Akt–B23 interaction enhances cell survival by preventing the
caspase-3 dependent degradation of B23 (Lee et al., 2008). In this
scenario, the interaction of Akt and B23 occurs between the N-
terminal PH domain of Akt and the C-terminus of B23, and,
importantly, requires Akt phosphorylation and nuclear translo-
cation as well as activation triggered by growth factor stimula-
tion (Lee et al., 2008). Interestingly, the kinase activity of Akt
was not required for this interaction and a constitutively active
Akt with phospho-mimetic mutations (T308D, S473D) strongly
bound B23 (Lee et al., 2008), indicating that a phosphorylation-
induced conformation change of Akt potentiates binding and
determines substrate specificity. The stabilization of B23 by Akt
is important as B23 directly interacts with c-Myc and stimulates
c-Myc-induced hyperproliferation and transformation (Li et al.,
2008). Just as Akt protects c-Myc from degradation by phos-
phorylating and excluding GSK-3 from the nucleus, facilitating
ribosome biogenesis (Wang et al., 1994; Gregory et al., 2003;
Bechard et al., 2012), Akt was shown to cooperate with c-Myc
to regulate fibroblast proliferation and transformation through
PI3K-dependent phosphorylation of the FOXO transcription fac-
tors (Brunet et al., 1999; Bouchard et al., 2004). Unphosphory-
lated FOXO proteins inhibit c-Myc-induced proliferation and
transformation and repress formation of the transcription preini-
tiation complex at the promoter site of certain genes including
cyclin D2 (Bouchard et al., 2004). Phosphorylation of FOXO by
Akt occurs downstream of PI3K activation and triggers FOXO
nuclear export thus derepressing multiple c-Myc target genes
(Bouchard et al., 2004).
Extracellular ATP, atorvastatin, and a purinergic receptor
P2X7 inhibitor were all shown to suppress cell growth by induc-
ing rapid depletion of phosphorylated nuclear Akt, a process
requiring nuclear localization of p110β (Ye et al., 2011). Nuclear
depletion of Akt was preceded by the nuclear localization of
PTEN, PHLPP, and calcineurin, and could be prevented by inhi-
bition of the scaffolding immunophilin FK506-binding protein
51 (FKBP51) or calcineurin (Mistafa et al., 2010). In these scenar-
ios, p110β can act as a scaffold between Akt and the phosphatases
PTEN, PP2A, and PHLPP1/2 (Gao et al., 2005; Brognard et al.,
2007; Mistafa et al., 2010; Kumar et al., 2011; Ye et al., 2011). This
may help to explain the function of the overexpression of p85β,
a regulatory subunit of PI3K, in cancers, where p85β and p110β
cooperate to retain activated nuclear Akt, facilitating cell survival,
cell cycle progression, and cell growth. It is plausible that the
requirement of p110β for depletion of nuclear Akt is a result of
its scaffolding role in the FKBP51-mediated interaction between
Akt and its phosphatase PHLPP, promoting dephosphorylation
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of nuclear Akt by PHLPP (Pei et al., 2009). The recently reported
feedback inhibition of PHLPP degradation by Akt-mediated
GSK-3β inactivation adds complexity to the evolving paradigm
(Li et al., 2009). It remains unclear if p110β-mediated nuclear
depletion of Akt is a mechanism for excess Akt sequestration
and if so, how this is related to nuclear PI3K activity-induced
Akt activation. Additionally, it is not known whether nuclear Akt
depletion is dependent on Akt dephosphorylation by PHLPPs.
A variety of human cancers exhibit increased nuclear accumu-
lation of Akt, a phenomenon that varies over the progression of
the pathological lesion (Ye et al., 2011). Copy number changes of
the genes encoding all three Akt isoforms were observed in estro-
gen receptor (ER)-positive breast carcinomas (Kirkegaard et al.,
2010). Amplification of Akt3 and deletions of Akt1 andAkt2 were
observed in breast carcinomas while Akt1 amplification was the
only observedAkt copy number alteration in prostate carcinomas
(Kirkegaard et al., 2010). In a mutational analysis for polymor-
phism, Akt2 mutations were identified in patient samples with
gastric or lung carcinomas (Soung et al., 2006). Overexpression
of Akt2 at the post-transcriptional level was found in oral squa-
mous cell carcinomas, where Akt3 mRNA was expressed at low
levels (Iamaroon and Krisanaprakornkit, 2009). These findings
collectively suggest a differential expression and regulatory pat-
tern of the Akt isoforms in different cancers, likely linked to the
nuclear activities of Akt.
The Akt activating factor PDK1, which phosphorylates Akt at
T308 in the cytoplasm, was found to shuttle between the cyto-
plasm and the nucleus (Lim et al., 2003). Nuclear-localized PDK1
was found to induce the formation of solid tumors and cor-
related with an increase in phosphorylated nuclear Akt, which
suppressed FOXO3A-mediated p27kip1 expression (Kikani et al.,
2012). While both cytoplasmic and nuclear PDK1 are able to
induce tumor formation, nuclear PDK1 is associated with higher-
risk tumors than cytoplasmic PDK1 (Kikani et al., 2012). These
findings indicate important roles of nuclear PDK1 in oncogenic
transformation and tumorigenesis, and warrant further inves-
tigation into the isoform-specific activation of nuclear Akts by
PDK1.
Prospects of Nuclear PI3K Signaling
It has been established that PI3K signaling plays essential roles in
cell growth and tumorigenesis. Both basic and clinical research
data suggest that the different PI3K and Akt isoforms as well
as their counteracting phosphatases and effector proteins are
spatially and temporally regulated within cells (Figure 3). These
kinases are expressed and regulated at different levels in different
cancer cells and are often genetically modified during cell trans-
formation. The complexity of this signaling nexus does follow a
pattern as subcellular targeting of specific PI3K and Akt isoforms
determines many if not all of the downstream signaling events.
Evidence for additional avenues of transduction beyond
the canonical PI3K/Akt signaling cascade has emerged. First,
PI3K/IPMK may signal to downstream effectors without acti-
vating Akt (Resnick et al., 2005; Mohan et al., 2013). Other sig-
naling pathways such as the MAPK/Erk cascade may crosstalk
with and/or be activated/deactivated through PI3K/Akt signal-
ing and inhibition (Mendoza et al., 2011). Consequently, com-
binational inhibition of the signaling pathways in the clinical
treatment of cancer patients has been introduced. These meth-
ods are promising in increasing the efficacy of treatments but, at
the same time, may cause complications (i.e., increased toxicity
FIGURE 3 | Molecular and biological functions of the nuclear PI3K
pathway. The cell nucleus harbors a PI3K pathway that is functionally
distinct from that of cytoplasm. The non-membranous localization of the
nuclear phosphoinositides PI(4,5)P2, PI(3,4)P2, and PI(3,4,5)P3 and their
kinases as well as phosphatases form hubs for channeling divergent
signaling to downstream molecular functions in the nucleus. These nuclear
activities, in turn, guide cell survival and many physio-pathological processes
including tumorigenesis.
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and chemoresistance) at both the molecular and systemic levels
(McCubrey et al., 2012; Saini et al., 2013). It must also be con-
sidered that PI3K, PTEN, and likely other proteins in the signal-
ing cascades have kinase- or phosphatase-independent functions
(Lindsay et al., 2006; Dou et al., 2010; Ye et al., 2011). Secondly,
there are additional upstream activating protein kinases that can
induce cell proliferation and malignancy through Akt indepen-
dent of PI3K (Mahajan and Mahajan, 2012). Third, as for many
oncogenes in certain types of cancers, PI3K or Akt hyperactiva-
tion requires additional signaling inputs, such as PTEN loss, to
induce tumor formation (Jia et al., 2008). Fourth, mutations in
different domains of a kinase in the cascade may alter the con-
formation of the protein in a way that requires specific co-factors
for activation, yielding distinct cancer phenotypes (Klarenbeek
et al., 2013). Notably, clinical observations are not always consis-
tent with the traditional views of PI3K/Akt activity. For exam-
ple, nuclear localization of activated Akt was associated with
long-term survival of breast cancer patients especially within the
ERα+/PR+ subgroup when compared with nuclear phosphory-
lated Akt-negative patients (Badve et al., 2010). Additional work
on the non-canonical roles of the PI3K signaling pathway will be
necessary for the development of more efficacious cancer treat-
ments. In contrast, downregulation of Akt isoforms sensitizes
chemoresistant endometrial carcinoma cells to chemotherapeu-
tic drugs (Girouard et al., 2013). It is intriguing that this seems
to be an isoform specific effect since constitutive Akt1 or Akt2
expression led to increased resistance to apoptosis (Girouard
et al., 2013), suggesting a possibility of selective targeting of
signaling molecules to increase chemo/radiation-sensitivity.
Encouraging progress has been made in defining nuclear
PI3K/Akt functions in cell growth and tumorigenesis. Neverthe-
less, many questions remain to be answered: To what degree do
the nuclear and cytosolic PI3K cascades complement or interfere
with one another during tumorigenesis? What other nuclear sig-
naling cascades coordinate and cross-regulate with the nuclear
PI3K pathway? How does the cell differentially regulate the
activities of highly homologous isoforms present in the same
subcellular compartment, as in the case of the Akt isoforms
in the nucleus? Similarly, how are the kinase- or phosphatase-
dependent and -independent functions of a single isoform sep-
arately regulated? How are the activities of specific kinases and
phosphatases balanced during tumorigenesis and pharmacolog-
ical treatment? Elucidating the nuclear PI3K pathway will com-
plement cytoplasmic findings and contribute to the development
of more effective clinical interventions against cancer.
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